Experience

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €3.6 billion aggregate principal amount of senior notes in three…

Davis Polk advised the representatives of the underwriters, in connection with the offering of €1 billion aggregate principal amount of notes issued by Merck & Co., Inc. The notes were…

Davis Polk advised the joint book-running managers in connection with a $100.1 million SEC-registered offering of 3,850,000 ordinary shares of Theravance Biopharma, Inc. The ordinary…

Davis Polk advised Roche Holdings, Inc. in connection with its Rule 144A/Regulation S offering of $650 million aggregate principal amount of 1.750% notes due 2022 and $850 million aggregate…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the initial public offering by iRhythm Technologies, Inc. iRhythm sold 7,238,235 shares…

Davis Polk advised Advanced Accelerator Applications S.A. on its approximately $150 million SEC-registered follow-on offering of American Depositary Shares representing its ordinary shares…

Davis Polk advised the joint book-running managers in connection with the $60 million follow-on offering of 4,898,000 shares of common stock of Versartis, Inc. at $12.25 per share. The…

Davis Polk advised AC Immune SA in connection with its $75.9 million U.S. initial public offering. AC Immune sold 6,900,000 of its common shares in the offering, which included 900,000…

Davis Polk advised Shire plc on the $12.1 billion SEC-registered debt offering by its wholly owned subsidiary, Shire Acquisitions Investments Ireland DAC (“SAIIDAC”), consisting of $3.3…

Davis Polk advised the representatives of the several underwriters, in connection with a secondary offering of 7,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of…